Literature DB >> 22051075

Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability.

C M Bonnín1, J Sánchez-Moreno, A Martínez-Arán, B Solé, M Reinares, A R Rosa, J M Goikolea, A Benabarre, J L Ayuso-Mateos, M Ferrer, E Vieta, C Torrent.   

Abstract

OBJECTIVE: To provide empirical evidence of the effect of subthreshold symptomatology (both depressive and manic) on psychosocial functioning, neurocognition and quality of life in bipolar disorder.
METHODS: A total of 133 participants were enrolled for this study (bipolar patients, n=103; healthy controls, n=30). Patients were divided into two groups according to their levels of subthreshold symptomatology: the subsyndromic group was constituted by those patients with upper levels of subthreshold symptomatology (HDRS≥4 and YMRS≥3) and the asymptomatic group represented the patients with lower scores (HDRS≤3 and YMRS≤2). All participants were administered a comprehensive neuropsychological battery. Moreover the patients answered the SF-36 (Quality of Life, QoL) and were interviewed with the WHODAS-2 (Psychosocial functioning and disability). One-way ANOVA were used in order to compare the differences between the three groups.
RESULTS: The analyses revealed that both patients groups, albeit free of acute symptoms of mania or depression, differed in terms of functioning and disability assessed with the WHODAS-2. Specifically, the total global score of disability was higher for the subsyndromic group indicating more impairment (p=0.008). The same pattern of impairment was found for three of its domains: "understanding and communicating" (p=0.013); "self-care" (p=0.035) and "getting along with others" (p=0.024). The subsyndromic group also scored lower when compared to their counterparts in the Mental Component of QoL of the SF-36 (p=0.045). Finally, in the neuropsychological performance verbal learning and memory was found to be impaired regardless the levels of subthreshold symptomatology, suggesting that this variable is a robust indicator of neuropsychological impairment in BD patients.
CONCLUSIONS: This report presents empirical data suggesting a moderate impact of subthreshold symptoms on functioning/disability and QoL and a discrete impact on neuropsychological impairment.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22051075     DOI: 10.1016/j.jad.2011.10.012

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  29 in total

1.  Cognitive deficits in first-degree relatives of bipolar patients: the use of homogeneous subgroups in the search of cognitive endophenotypes.

Authors:  Julia Volkert; J Haubner; J Kazmaier; F Glaser; J Kopf; S Kittel-Schneider; A Reif
Journal:  J Neural Transm (Vienna)       Date:  2016-06-08       Impact factor: 3.575

Review 2.  Treatment of Functional Impairment in Patients with Bipolar Disorder.

Authors:  Jose Sanchez-Moreno; Anabel Martinez-Aran; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2017-01       Impact factor: 5.285

3.  Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder.

Authors:  Andrea Murru; Isabella Pacchiarotti; Norma Verdolini; Maria Reinares; Carla Torrent; Pierre-Alexis Geoffroy; Frank Bellivier; Pierre-Michel Llorca; Eduard Vieta; Ludovic Samalin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-22       Impact factor: 5.270

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

5.  Neurocognitive functioning in individuals with bipolar disorder and their healthy siblings: A preliminary study.

Authors:  Isabelle E Bauer; Mon-Ju Wu; T W Frazier; Benson Mwangi; Danielle Spiker; Giovana B Zunta-Soares; Jair C Soares
Journal:  J Affect Disord       Date:  2016-04-27       Impact factor: 4.839

6.  Evidence for the continuous latent structure of mania and depression in out-patients with bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  J J Prisciandaro; B K Tolliver
Journal:  Psychol Med       Date:  2015-04-17       Impact factor: 7.723

7.  Cognitive deficits in bipolar disorder: from acute episode to remission.

Authors:  J Volkert; M A Schiele; Julia Kazmaier; Friederike Glaser; K C Zierhut; J Kopf; S Kittel-Schneider; A Reif
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-26       Impact factor: 5.270

Review 8.  Neurocognitive functioning in euthymic patients with bipolar disorder and unaffected relatives: A review of the literature.

Authors:  Stephanie A Cardenas; Layla Kassem; Melissa A Brotman; Ellen Leibenluft; Francis J McMahon
Journal:  Neurosci Biobehav Rev       Date:  2016-08-05       Impact factor: 8.989

9.  The impact of repeated manic episodes and executive dysfunction on work adjustment in bipolar disorder.

Authors:  C M Bonnín; C Torrent; J M Goikolea; M Reinares; B Solé; M Valentí; J Sánchez-Moreno; D Hidalgo; R Tabarés-Seisdedos; A Martínez-Arán; E Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-03       Impact factor: 5.270

10.  Performance of Bipolar Disorder Patients in Attention Testing: Comparison with Normal Controls and Among Manic, Depressive, and Euthymic Phases.

Authors:  Evelyn V M Camelo; Daniel Mograbi; Rafael de Assis da Silva; Jaqueline Bifano; Mayra Wainstok; Luciana Angélica Silva Silveira; Tânia Netto; Cristina M T Santana; Elie Cheniaux
Journal:  Psychiatr Q       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.